Hospitalized cocaine detoxification patients in Paris, France: Increased patient levels and changing population characteristics since 2011.

Cocaine Epidemiology Hospitalization Psychostimulant Substance use disorders

Journal

Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544

Informations de publication

Date de publication:
26 Mar 2024
Historique:
received: 15 12 2023
revised: 08 02 2024
accepted: 18 03 2024
medline: 7 4 2024
pubmed: 7 4 2024
entrez: 6 4 2024
Statut: aheadofprint

Résumé

The past twenty years have seen a rise in cocaine-related statistics in France, including cocaine use in the general population, emergency ward presentations of acute cocaine intoxication, cocaine use disorders related outpatient appointments and cocaine-related deaths. This study's objectives were to describe trends in patients' admission for specific cocaine detoxification as well as changes in patients' characteristics in the Assistance publique-Hôpitaux de Paris (AP-HP) hospitals group located in Paris region, France. We reviewed the international classification of diseases 10 The regional database showed an almost 3-fold increase in cocaine-related disorders discharge codes between 2011 and 2019. This occurred due to a rise in hospital stays for cocaine dependence or cocaine acute intoxication prior to the fall in levels of inpatient stays associated with the coronavirus disease 2019 (COVID-19) pandemic. The in-depth analysis of inpatients' stays in the specialized addiction medicine ward also showed an increase in admissions for cocaine detoxification programs, with a prevalence of 1.19% in 2009 to 15.73% in 2022 (P=1.44×10 The referral to hospital care for cocaine detoxification has increased in Paris region since 2011, coupled with changes in inpatients' characteristics. This trend has significant implications for the management of inpatient hospital services.

Identifiants

pubmed: 38582619
pii: S0040-5957(24)00038-6
doi: 10.1016/j.therap.2024.03.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Virgile Clergue-Duval (V)

Département de Psychiatrie et de Médecine Addictologique, site Lariboisière Fernand-Widal, APHP GHU Nord, Université Paris Cité, 75010 Paris, France; UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM, Université Paris Cité, 75006 Paris, France; FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France; UFR de Médecine, Université Paris Cité, 75006 Paris, France. Electronic address: virgile.clergue-duval@aphp.fr.

Arthur Lyonnet (A)

Département de Psychiatrie et de Médecine Addictologique, site Lariboisière Fernand-Widal, APHP GHU Nord, Université Paris Cité, 75010 Paris, France; FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Julien Azuar (J)

Département de Psychiatrie et de Médecine Addictologique, site Lariboisière Fernand-Widal, APHP GHU Nord, Université Paris Cité, 75010 Paris, France; UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM, Université Paris Cité, 75006 Paris, France; FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Romain Icick (R)

Département de Psychiatrie et de Médecine Addictologique, site Lariboisière Fernand-Widal, APHP GHU Nord, Université Paris Cité, 75010 Paris, France; UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM, Université Paris Cité, 75006 Paris, France; FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Margaux Poireau (M)

UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM, Université Paris Cité, 75006 Paris, France; FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Dorian Rollet (D)

Département de Psychiatrie et de Médecine Addictologique, site Lariboisière Fernand-Widal, APHP GHU Nord, Université Paris Cité, 75010 Paris, France; UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM, Université Paris Cité, 75006 Paris, France; FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Namik Taright (N)

APHP, Department of Medical Information, 75012 Paris, France.

Frank Questel (F)

Département de Psychiatrie et de Médecine Addictologique, site Lariboisière Fernand-Widal, APHP GHU Nord, Université Paris Cité, 75010 Paris, France; UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM, Université Paris Cité, 75006 Paris, France; FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.

Isabelle Gasquet (I)

APHP, Department of Medical Information, 75012 Paris, France.

Florence Vorspan (F)

Département de Psychiatrie et de Médecine Addictologique, site Lariboisière Fernand-Widal, APHP GHU Nord, Université Paris Cité, 75010 Paris, France; UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM, Université Paris Cité, 75006 Paris, France; FHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France; UFR de Médecine, Université Paris Cité, 75006 Paris, France.

Classifications MeSH